

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
7 October 2004 (07.10.2004)

PCT


(10) International Publication Number
WO 2004/085505 A2

- (51) International Patent Classification⁷: **C08G**
- (21) International Application Number: PCT/US2004/008847
- (22) International Filing Date: 24 March 2004 (24.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/456,472 24 March 2003 (24.03.2003) US
60/456,952 25 March 2003 (25.03.2003) US
60/518,892 10 November 2003 (10.11.2003) US
- (71) Applicant (for all designated States except US): SE-
QUOIA PHARMACEUTICALS, INC. [US/US]; 401
Professional Drive, Suite 100, Gaithersburg, MD 20879
(US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SILVA, Abelardo
[US/US]; 2933 Excelsior Spring Court, Ellicott City, MD
21042 (US). ERICKSON, John, E. [US/US]; 10833 Stan-
more Drive, Potomac, MD 20854 (US). EISSENSTAT,
Michael [US/US]; 8110 Claiborne Court, Frederick, MD
21702 (US). AFONINA, Elena [US/US]; 8004 Mead-
owview Drive, Frederick, MD 21702 (US). GULNIK,
- Sergel [US/US]; 8004 Meadowview Drive, Frederick, MD
21702 (US).
- (74) Agents: BOOTH, Paul, M. et al.; Heller Ehrman White &
McAuliffe LLP, 1666 K Street, N.W., Suite 300, Washing-
ton, DC 20006-1228 (US).
- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.
- (84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: LONG ACTING BIOLOGICALLY ACTIVE CONJUGATES

Pharmacokinetics of unconjugated (SPI-30014Q) vs HSA-conjugated (SPI30014HSA) fusion inhibitor peptide in Sprague-Dawley rats



(57) Abstract: The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity *in vivo*. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein. The complexes are prepared by conjugating a biologically active moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein. The complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule. The invention also provides anti-viral compounds that are inhibitors of viral infection and/or exhibit anti-fusiogenic properties. In particular, this invention provides compounds having inhibiting activity against viruses such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) and that have extended duration of action for the treatment of viral infections.